Geniposide attenuates oligomeric Aβ1-42-induced inflammatory response by targeting RAGE-dependent signaling in BV2 cells

Current Alzheimer Research

Volumn 11, Issue 5, 2014, Pages 430-440

  Lv, Cui ^a,b,c   Wang, Lei ^b,c   Liu, Xiaoli ^a,b,c   Cong, Xiao ^c   Yan, Shirley ShiDu ^a,d   Wang, Yongyan ^a,b   Zhang, Wensheng ^a,b,c  

^a BEIJING NORMAL UNIVERSITY   (China)

^b Beijing Area Major Laboratory of Protection and Utilization of Traditional Chinese Medicine   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d UNIVERSITY OF KANSAS   (United States)

Author keywords

Alzheimer's disease; Geniposide; Inflammatory responses; RAGE; RAGE dependent signaling pathway

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN[1-42]; GENIPOSIDE; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; OLIGOMER; TUMOR NECROSIS FACTOR ALPHA; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN RECEPTOR; IRIDOID; MESSENGER RNA; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG TARGETING; GARDENIA; IMMUNOPRECIPITATION; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; CELL COUNT; CELL LINE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; NEUROBLASTOMA; PATHOLOGY;

AMYLOID BETA-PEPTIDES; ANIMALS; CELL COUNT; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GENE EXPRESSION REGULATION; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOPRECIPITATION; INTERLEUKIN-1BETA; IRIDOIDS; MICE; MICROGLIA; NEUROBLASTOMA; PEPTIDE FRAGMENTS; RECEPTORS, IMMUNOLOGIC; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904045384     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011666140514111204     Document Type: Article

References (44)

1. Eikelenboom P, Zhan SS, van Gool WA, Allsop D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol Sci 15(12): 447-450 (1994).
2. Eikelenboom P, Veerhuis R. The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol Aging 17(5): 673-680 (1996).
3. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. The Am J Psychiatry 151(8): 1105-1113 (1994).
4. McGeer EG, McGeer PL. The importance of inflammatory mechanisms in Alzheimer disease. Exp Gerontol 33(5): 371-378 (1998).
5. Glezer I, Simard AR, Rivest S. Neuroprotective role of the innate immune system by microglia. Neuroscience 147(4): 867-883 (2007).
6. Eikelenboom P, van Gool WA. Neuroinflammatory perspectives on the two faces of Alzheimer's disease. J Neural Transm 111(3): 281-294 (2004).
7. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Dewachter I, Walter J, Klockgether T, et al. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation 2: 22 (2005).
8. Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol 64(9): 743-753 (2005).
9. Stalder M, Phinney A, Probst A, Sommer B, Staufenbiel M, Jucker M. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol 154(6): 1673-1684 (1999).
10. Vehmas AK, Kawas CH, Stewart WF, Troncoso JC. Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol Aging 24(2): 321-331 (2003).
11. Arancio O, Zhang HP, Chen X, Lin C, Trinchese F, Puzzo D, et al. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 23(20): 4096-4105 (2004).
12. Fang F, Lue LF, Yan S, Xu H, Luddy JS, Chen D, et al. RAGEdependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB journal: official publication of the Federation of American Societies for Exp Biol 24(4): 1043-1055 (2010).
13. Yan SS, Chen D, Yan S, Guo L, Du H, Chen JX. RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer's disease. Frontiers Biosci 4: 240-250 (2012).
14. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9(7): 907-913 (2003).
15. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267(21): 14998-15004 (1992).
16. Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 106(5): 842-853 (2010).
17. Park H, Adsit FG, Boyington JC. The 1. 5 A crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding. J Biol Chem 285(52): 40762-40770 (2010).
18. Koch M, Chitayat S, Dattilo BM, Schiefner A, Diez J, Chazin WJ, et al. Structural basis for ligand recognition and activation of RAGE. Structure 18(10): 1342-1352 (2010).
19. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382(6593): 685-691 (1996).
20. Origlia N, Capsoni S, Cattaneo A, Fang F, Arancio O, Yan SD, et al. Abeta-dependent Inhibition of LTP in different intracortical circuits of the visual cortex: the role of RAGE. Journal of Alzheimer's disease: JAD 17(1): 59-68 (2009).
21. Origlia N, Bonadonna C, Rosellini A, Leznik E, Arancio O, Yan SS, et al. Microglial receptor for advanced glycation end productdependent signal pathway drives beta-amyloid-induced synaptic depression and long-term depression impairment in entorhinal cortex. J Neurosci 30(34): 11414-11425 (2010).
22. Origlia N, Righi M, Capsoni S, Cattaneo A, Fang F, Stern DM, et al. Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci 28(13): 3521-3530 (2008).
23. Koo HJ, Lim KH, Jung HJ, Park EH. Anti-inflammatory evaluation of gardenia extract, geniposide and genipin. J Ethnopharmacol 103(3): 496-500 (2006).
24. Liu J, Yin F, Zheng X, Jing J, Hu Y. Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway. Neurochem Internat 51(6-7): 361-369 (2007).
25. Peng CH, Huang CN, Hsu SP, Wang CJ. Penta-acetyl geniposideinduced apoptosis involving transcription of NGF/p75 via MAPKmediated AP-1 activation in C6 glioma cells. Toxicology 238(2-3): 130-139 (2007).
26. Wang J, Hou J, Zhang P, Li D, Zhang C, Liu J. Geniposide reduces inflammatory responses of oxygen-glucose deprived rat microglial cells via inhibition of the TLR4 signaling pathway. Neurochem Res 37(10): 2235-2248 (2012).
27. Dahlgren KN, Manelli AM, Stine WB, Jr., Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 277(35): 32046-32053 (2002).
28. Yin F, Liu J, Ji X, Wang Y, Zidichouski J, Zhang J. Silibinin: a novel inhibitor of Abeta aggregation. Neurochem Int 58(3): 399-403 (2011).
29. Ishihara K, Tsutsumi K, Kawane S, Nakajima M, Kasaoka T. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett 550(1-3): 107-113 (2003).
30. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 274(28): 19919-19924 (1999).
31. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 21(3): 383-421 (2000).
32. Schwab C, McGeer PL. Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J Alzheimers Dis 13(4): 359-369 (2008).
33. Wang GF, Wu SY, Xu W, Jin H, Zhu ZG, Li ZH, et al. Geniposide inhibits high glucose-induced cell adhesion through the NF-kappaB signaling pathway in human umbilical vein endothelial cells. Acta Pharmacol Sin 31(8): 953-962 (2010).
34. Fu Y, Liu B, Liu J, Liu Z, Liang D, Li F, et al. Geniposide, from Gardenia jasminoides Ellis, inhibits the inflammatory response in the primary mouse macrophages and mouse models. Int Immunopharmacol 14(4): 792-798 (2012).
35. Zheng X, Yang D, Liu X, Wang N, Li B, Cao H, et al. Identification of a new anti-LPS agent, geniposide, from Gardenia jasminoides Ellis, and its ability of direct binding and neutralization of lipopolysaccharide in vitro and in vivo. Int Immunopharmacol 10(10): 1209-1219 (2010).
36. Cho HJ, Son SM, Jin SM, Hong HS, Shin DH, Kim SJ, et al. RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model. FASEB J 23(8): 2639-2649 (2009).
37. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 109: S81-96 (2002).
38. Zhao Q, Lee FS. Mitogen-activated protein kinase/ERK kinase kinases 2 and 3 activate nuclear factor-kappaB through IkappaB kinase-alpha and IkappaB kinase-beta. J Biol Chem 274(13): 8355-8358 (1999).
39. Lee FS, Hagler J, Chen ZJ, Maniatis T. Activation of the IkappaB alpha kinase complex by MEKK1, a kinase of the JNK pathway. Cell 88(2): 213-222 (1997).
40. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 272(26): 16498-16506 (1997).
41. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 83(11): 876-886 (2005).
42. Schmidt AM, Sahagan B, Nelson RB, Selmer J, Rothlein R, Bell JM. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease. Curr Opin Investig Drugs 10(7): 672-680 (2009).
43. Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord 25(3): 206-212 (2011).
44. Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, et al. A multimodal RAGE-specific inhibitor reduces amyloid betamediated brain disorder in a mouse model of Alzheimer disease. J Clin Investig 122(4): 1377-1392 (2012).